KindlyMD (NASDAQ:NAKA – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.05), Zacks reports. KindlyMD had a negative return on equity of 131.09% and a negative net margin of 244.00%.
KindlyMD Trading Down 4.2%
NASDAQ:NAKA traded down $0.02 on Wednesday, reaching $0.54. The company’s stock had a trading volume of 8,581,196 shares, compared to its average volume of 9,180,055. The firm has a market capitalization of $236.11 million, a price-to-earnings ratio of -0.62 and a beta of 30.71. KindlyMD has a 12-month low of $0.52 and a 12-month high of $34.77. The company has a 50 day moving average of $1.12.
Analyst Ratings Changes
Several brokerages recently commented on NAKA. Maxim Group began coverage on KindlyMD in a research report on Wednesday, September 3rd. They set a “buy” rating and a $8.00 price target for the company. Wall Street Zen upgraded shares of KindlyMD to a “sell” rating in a report on Saturday, October 18th. B. Riley began coverage on KindlyMD in a report on Wednesday, October 15th. They set a “buy” rating and a $2.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of KindlyMD in a research report on Wednesday, October 8th. Finally, Zacks Research raised KindlyMD to a “hold” rating in a report on Friday, October 17th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, KindlyMD presently has an average rating of “Hold” and an average target price of $5.00.
KindlyMD Company Profile
Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.
Read More
- Five stocks we like better than KindlyMD
- Growth Stocks: What They Are, Examples and How to Invest
- HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
- What is the S&P/TSX Index?
- End the Year Strong With These 3 Comeback Champions
- The Role Economic Reports Play in a Successful Investment Strategy
- Down 45% Year-to-Date, Novo Nordisk Ignites a Price War
Receive News & Ratings for KindlyMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KindlyMD and related companies with MarketBeat.com's FREE daily email newsletter.
